

## Sudan South Support for Injection Safety Devices

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Sudan South				
<b>2. Grant number:</b> 17-SDS-32a-X / 18-SDS-32a-X/ 19-SDS-32a-X / 20-SDS-32a-X				
<b>3. Date of Decision Letter:</b> 21 January 2019				
<b>4. Date of the Partnership Framework Agreement:</b> 24 June 2013				
<b>5. Programme title:</b> Injection safety devices <sup>1</sup>				
<b>6. Programme duration<sup>2</sup>:</b> 2017-2019				
<b>7. Programme Budget (indicative):</b> (subject to the terms of the partnership framework agreement, if applicable)				
	2017-2018	2019	2020	Total <sup>3</sup>
Programme Budget (US\$)	329,000	103,500	39,500	472,000
<b>8. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>				
<b>TOTAL injection safety devices to be purchased with Gavi funds in each year</b>	<b>2017-2018</b>	<b>2019</b>		
Number of AD syringes		2,025,400		
Number of re-constitution syringes		224,900		
Number of safety boxes		24,775		
<b>Annual Amounts for injection safety devices for all Gavi vaccines (US\$)</b>	<b>329,000</b>	<b>103,500</b>		
<b>Injection safety devices to be purchased with Gavi funds in each year, <u>by type of support</u></b>				

<sup>1</sup> This does not include vaccines.

<sup>2</sup> This is the entire duration of the Programme.

<sup>3</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>4</sup> This is the amount that Gavi has approved.

<b>New Vaccine Support (NVS), Measles, 10 doses per vial, LYOPHIZED, Follow-Up Campaign</b>	<b>2019</b>
Number of AD syringes	2,025,400
Number of re-constitution syringes	224,900
Number of safety boxes	24,775
Annual Amounts for injection safety devices for Vaccine (US\$)	103,500

**9. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

**10. Self-procurement:** N/A

**11. Co-financing obligations:** Co-financing requirements are listed in the relevant vaccine Decision Letter.

On behalf of Gavi



Hind Khatib-Othman  
Managing Director, Country Programmes  
21 January 2019